About the 2023 POPIA Program


Two grants will be awarded in 2023 to accelerate initiatives that are focused on improving access to precision oncology care and tackling inequalities for children with cancer around the world.

The 2023 awards will be awarded to innovative programs tackling access to biomarker testing in the following cancer types:

lung cancer

Pediatric Cancers (solid tumours) that are known to harbor rare, actionable genomic alterations. Types of genomic alterations can include mutations (e.g., KRAS, BRAF, EGFR), gene fusions (e.g., ROS1, NTRK, FGFR, RET), and many more.

Apply for the Precision Oncology Patient Innovation Awards

View more details on how to apply

Next Important Date

June 30, 2023 – Deadline for initial applications

Submissions must be received no later than 12:00 AM (midnight) Eastern Standard Time

See all important dates and deadlines

Applications will be reviewed by an independent, non-Bayer review panel composed of experienced representatives from the clinical and patient advocacy communities.

Duration of Award: 1 Year

Award Value: Two awards in the amount of $50,000 USD each.

2023 POPIA Program Timeline

Action Dates
Applications open April 24, 2023
Deadline for entries June 30, 2023
Applications reviewed by REVIEW PANEL July 25, 2023
Applicants chosen to submit a full proposal July 25, 2023
Full Proposal submission deadline August 15, 2023
Applicants notified of decision September 1, 2023

Apply for the Precision Oncology Patient Innovation Awards

View more details on how to apply

Next Important Date

June 10, 2022 – Deadline for initial applications

Submissions must be received no later than 12:00 AM (midnight) EDT

See all important dates and deadlines
    lung cancer

    Improve access to tumor testing to inform patient diagnosis and care

    Playbook icon

    Address inequalities and barriers in precision medicine that impact cancer communities


    Lightbulb Icon

    Improve community education, training, and awareness in precision medicine, including tumor tissue testing for genomic and oncogenic drivers

      Applications will be accepted from NGOs that are Non-governmental patient organizations and Non-governmental healthcare institutions, unless prohibited by national law.


      Applications from individuals will not be allowed.


      Collaborations between institutions, including between patient groups and research facilities, are welcome.


      Please designate a lead organization in the application.


      Learn more about the application process

        You may apply to support a new initiative or to support the continued rollout/expansion of an existing program. Applying for the grant does not preclude you from seeking other sources of funding. Although the award is for 1 year, your program can continue beyond the year.

        Initiatives should be focused on precision oncology and may include, but are not limited to:

        • Health intervention programs such as a community testing or community training program
        • Testing algorithm tool
        • Survey
        • Communications tool (eg, help to interpret complex information on cancer type or tests)
        • Public health initiative
        • Education resources for healthcare professionals or patients/care partners (eg, online tool, infographic, website, animation, events, printed materials)
        • Awareness campaign
        • Digital health/technology project publication

        Interventional clinical trials and translational research studies are not included in the awards.


        Bayer provides other forms of scientific partnership in focused areas of research, which are listed on its corporate website.

          The grant amount requested in funding cannot exceed 25% of an organization’s overall funding.


          Program must be nonpromotional and should not include mention of any particular medicine. Program may refer to class of treatment.


          Program should be initiated within 1 year of receiving funds, and metrics should be reported by an agreed-upon date.


          Applications should comply with program criteria.

            Successful applicants will be announced publicly. Bayer will make every effort to help successful applicants share their programs with the wider cancer community.